Taxotere Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers
Condition: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Interventions: Drug: HMBD-001; Drug: Docetaxel; Drug: Cetuximab Sponsors: Hummingbird Bioscience; Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 20, 2023 Category: Research Source Type: clinical trials

Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC
Condition: Advanced Non-Small Cell Lung Cancer Interventions: Drug: Trilaciclib+Envafolimab+Docetaxel; Drug: Envafolimab+Docetaxel; Drug: Docetaxel Sponsor: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 19, 2023 Category: Research Source Type: clinical trials

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers
Condition: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Interventions: Drug: HMBD-001; Drug: Docetaxel; Drug: Cetuximab Sponsors: Hummingbird Bioscience; Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 19, 2023 Category: Research Source Type: clinical trials